There were 138 press releases posted in the last 24 hours and 357,567 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Cyclacel Doses First Patient in Phase 1 Trial of Its Novel CDK2/9 Inhibitor, CYC065, for the Treatment of Advanced Solid Tumors

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image